Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
OPHLF Ono Pharmaceutical	$10.38	$11.23	$9.20 ▼ $16.05	$4.87B	0.6	8,600 shs	N/A
RPRX Royalty Pharma	$32.45 +0.4%	$32.40	$24.05 ▼ $34.32	$18.63B	0.49	3.47 million shs	2.51 million shs
SMMT Summit Therapeutics	$25.85 +0.3%	$23.00	$2.10 ▼ $36.91	$19.20B	-0.94	3.90 million shs	1.76 million shs
TEVA Teva Pharmaceutical Industries	$16.95 +0.0%	$15.38	$12.47 ▼ $22.80	$19.21B	0.62	9.98 million shs	6.48 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
OPHLF Ono Pharmaceutical	0.00%	-3.28%	-12.13%	+4.83%	-27.98%
RPRX Royalty Pharma	+0.43%	-4.61%	+2.40%	-2.90%	+18.73%
SMMT Summit Therapeutics	+0.31%	+8.29%	-22.31%	+16.86%	+488.84%
TEVA Teva Pharmaceutical Industries	+0.03%	-0.02%	+18.50%	+1.19%	+0.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	4.7557 of 5 stars	3.5	3.0	3.3	3.7	2.9	1.7	1.9
SMMT Summit Therapeutics	3.0363 of 5 stars	4.5	2.0	0.0	0.0	3.7	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.2946 of 5 stars	3.6	5.0	0.8	0.0	3.4	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
OPHLF Ono Pharmaceutical	0.00	N/A	N/A	N/A
RPRX Royalty Pharma	3.00	Buy	$42.50	30.97% Upside
SMMT Summit Therapeutics	3.09	Buy	$37.40	44.68% Upside
TEVA Teva Pharmaceutical Industries	3.13	Buy	$24.43	44.16% Upside

Current Analyst Ratings Breakdown

Latest OPHLF, RPRX, TEVA, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$51.00
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
4/28/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00 ➝ $40.00
4/28/2025	TEVA Teva Pharmaceutical Industries	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/25/2025	SMMT Summit Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$31.00 ➝ $44.00
4/23/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/28/2025	RPRX Royalty Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
OPHLF Ono Pharmaceutical	$3.48B	1.40	$1.97 per share	5.28	$11.54 per share	0.90
RPRX Royalty Pharma	$2.26B	8.26	$4.09 per share	7.94	$17.94 per share	1.81
SMMT Summit Therapeutics	$700K	27,425.59	N/A	N/A	$0.11 per share	235.00
TEVA Teva Pharmaceutical Industries	$16.62B	1.16	$3.36 per share	5.05	$4.75 per share	3.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
OPHLF Ono Pharmaceutical	$883.05M	$0.70	9.98	∞	N/A	15.15%	9.10%	7.12%	7/28/2025 (Estimated)
RPRX Royalty Pharma	$858.98M	$1.85	22.38	6.68	2.31	37.94%	24.40%	14.01%	N/A
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.44	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest OPHLF, RPRX, TEVA, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	RPRX Royalty Pharma	$0.99	$1.06	+$0.07	$0.41	$724.69 million	$839.00 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.71%	+7.30%	47.57%	5 Years
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.97%	N/A	N/A	N/A

Latest OPHLF, RPRX, TEVA, and SMMT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/21/2025	RPRX Royalty Pharma	quarterly	$0.22	2.7%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
OPHLF Ono Pharmaceutical	0.14	3.55	2.80
RPRX Royalty Pharma	0.64	1.44	1.44
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
OPHLF Ono Pharmaceutical	N/A
RPRX Royalty Pharma	54.35%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
OPHLF Ono Pharmaceutical	N/A
RPRX Royalty Pharma	18.90%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
OPHLF Ono Pharmaceutical	3,853	469.71 million	N/A	Not Optionable
RPRX Royalty Pharma	80	576.45 million	477.83 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

OPHLF, RPRX, TEVA, and SMMT Headlines

Recent News About These Companies

Worldquant Millennium Advisors LLC Invests $4.96 Million in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 24 at 5:15 AM | marketbeat.com

Why Investors Should Watch Teva Despite Regional Risks

May 23 at 1:10 PM | seekingalpha.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Two Sigma Advisers LP

May 23 at 5:37 AM | marketbeat.com

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 22 at 1:56 PM | globenewswire.com

Soleus Capital Management L.P. Buys New Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 21 at 8:07 AM | marketbeat.com

Nuveen Asset Management LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 21 at 4:55 AM | marketbeat.com

Brokerages Set Teva Pharmaceutical Industries Limited (NYSE:TEVA) Target Price at $24.43

May 21 at 2:31 AM | americanbankingnews.com

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

May 20, 2025 | globenewswire.com

Teva Pharmaceutical Industries Ltd (TEVA) Receives Credit Rating Upgrade from Fitch | TEVA ...

May 20, 2025 | gurufocus.com

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

May 20, 2025 | globenewswire.com

Fitch upgrades Teva’s rating to ’BB+’ with stable outlook

May 20, 2025 | investing.com

Tema Etfs LLC Purchases New Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 20, 2025 | marketbeat.com

27,722 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Siemens Fonds Invest GmbH

May 20, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Lazard Asset Management LLC

May 20, 2025 | marketbeat.com

Jefferies Financial Group Inc. Takes $332,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

May 20, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Rating of "Buy" by Brokerages

May 20, 2025 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

May 19, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. Plans $2 Billion Senior Notes Offering to Finance Debt Tender Offers

May 19, 2025 | quiverquant.com

Teva Pharmaceutical Industries Ltd. Launches Tender Offers for $2 Billion in Senior Notes to Optimize Debt Structure

May 19, 2025 | quiverquant.com

TevaÂ AnnouncesÂ $2,000,000,000 (Equivalent) DebtÂ TenderÂ OffersÂ For Notes Due 2026-2031

May 19, 2025 | globenewswire.com

TevaÂ AnnouncesÂ LaunchÂ ofÂ $2,000,000,000 (Equivalent) OfferingÂ ofÂ Senior Notes

May 19, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPHLF, RPRX, TEVA, and SMMT Company Descriptions

Ono Pharmaceutical OTCMKTS:OPHLF

$10.38 0.00 (0.00%)

As of 05/23/2025

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Royalty Pharma NASDAQ:RPRX

$32.45 +0.14 (+0.43%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$31.80 -0.65 (-2.00%)

As of 05/23/2025 07:31 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$25.85 +0.08 (+0.31%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$25.72 -0.14 (-0.52%)

As of 05/23/2025 07:49 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$16.94 +0.01 (+0.03%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$17.00 +0.05 (+0.32%)

As of 05/23/2025 07:58 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time